Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD

January 13, 2025

Sergio A. Giralt, MD

Opinion

Video

Sergio A. Giralt, MD, discusses how he selects patients with chronic graft-vs-host disease (cGVHD) for treatment with ruxolitinib, often in combination with corticosteroids, and reviews the study design and methods of recent research on ruxolitinib in cGVHD management, highlighting key efficacy and safety results and how these findings align with his clinical practice.

EP: 1.The Pathophysiology of Chronic Graft-Vs -Host Disease (cGVHD) and the Role of CSF1R

EP: 2.Examining Axatilimab in the AGAVE-201 Trial For cGVHD

EP: 3.Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD

Now Viewing

EP: 4.Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD

EP: 5.The Role of Posttransplant Cyclophosphamide in Patients With cGVHD

EP: 6.Main Conference Takeaways Regarding cGVHD Management

Video content above is prompted by the following:

Which patients with chronic graft-vs-host disease (cGVHD) do you treat with ruxolitinib in your clinical practice?
Do you use corticosteroids concurrently with ruxolitinib?
What were this abstract’s study design and methods, and why was it important to investigate for cGVHD management?
What were the key efficacy and safety results seen in this abstract?
Do these results align with what you see in your clinical practice?

Related Content

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

ICYMI: Highlights From ASCO 2024

December 21st 2024

Article

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

ICYMI: Highlights From SLEEP 2024

December 18th 2024

Article

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

ICYMI: Highlights From ACTRIMS 2024

December 12th 2024

Article

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).